Retroperitoneal Lymph Node Dissection for Testicular Seminoma

Not currently recruiting at 13 trial locations

Age: Any Age

Sex: Male

Trial Phase: Academic

Sponsor: University of Southern California

Disqualifiers: Second malignancy, Chemotherapy, Radiotherapy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

Duration: 1 day

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores the effectiveness of a surgical procedure called retroperitoneal lymph node dissection (RPLND) for treating testicular seminoma, a type of testicular cancer. The researchers aim to determine if this surgery can remove cancer-spreading lymph nodes behind the intestines while minimizing long-term health issues like second cancers or heart problems. The trial seeks participants who have undergone testicular seminoma surgery and either have isolated lymph node issues in the retroperitoneum or a recent cancer relapse in that area. As an unphased trial, this study offers a unique opportunity to contribute to medical knowledge and potentially benefit future patients.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, if you are taking investigational agents or have uncontrolled illnesses, you may not be eligible to participate.

What prior data suggests that retroperitoneal lymph node dissection is safe for treating testicular seminoma?

Research has shown that retroperitoneal lymph node dissection (RPLND) is generally safe for patients with testicular seminoma. Studies have found low complication rates and promising cure rates for early-stage seminomas with this surgery. For instance, robotic RPLND often results in fewer serious complications and shorter hospital stays. One study noted good survival rates without increasing the risk of cancer recurrence. When performed at experienced centers, RPLND carries a low risk of short- or long-term problems. Overall, these findings suggest that RPLND is well-tolerated and safe for treating testicular seminoma. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Retroperitoneal Lymph Node Dissection (RPLND) is unique because it offers a surgical approach to treat testicular seminoma by directly removing potentially cancerous lymph nodes from the retroperitoneal area. Unlike standard treatments like chemotherapy or radiation, which target cancer cells throughout the body, RPLND is a precise procedure targeting a specific area, potentially reducing the exposure to systemic side effects. Researchers are excited about RPLND because it could offer a more targeted treatment option that minimizes the long-term side effects associated with traditional therapies, improving quality of life for patients.

What evidence suggests that retroperitoneal lymph node dissection is effective for treating testicular seminoma?

Research has shown that retroperitoneal lymph node dissection (RPLND), which participants in this trial will undergo, is a safe and effective treatment for patients with early-stage testicular seminoma, specifically stages I-IIa. Studies have found that this surgery can lead to high cure rates while minimizing long-term side effects. Patients who undergo RPLND report fewer issues like secondary cancers or heart problems compared to those receiving other treatments. This procedure also effectively removes cancerous lymph nodes in the retroperitoneum, the first area where seminoma typically spreads. Overall, current evidence suggests that RPLND is a promising option for treating early-stage testicular seminoma. ^{1 5 6 7 8}

Who Is on the Research Team?

Siamak Daneshmand

Principal Investigator

University of Southern California

Are You a Good Fit for This Trial?

This trial is for patients with stage I-IIa testicular seminoma who've had an orchiectomy and show signs of cancer spread to lymph nodes in the retroperitoneum. Eligible participants should not have received prior chemotherapy or radiotherapy, must be within three years of initial diagnosis, and have good overall health as indicated by ECOG status.

Inclusion Criteria

If I had a biopsy, it showed pure seminoma.

My recent chest scans show no signs of cancer spread.

I can carry out all my self-care but cannot do heavy physical work.

Exclusion Criteria

I do not have any serious illnesses or social situations that would stop me from following the study's requirements.

I have had chemotherapy or radiotherapy in the past.

Patients receiving any other investigational agent(s)

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Patients undergo retroperitoneal lymph node dissection (RPLND) as first-line treatment for testicular seminoma

1 day

1 visit (in-person)

Follow-up

Participants are monitored for recurrence and complications after RPLND

5 years

1 visit at 1 month, every 4 months for 1 year, every 6 months for 2 years, then annually

What Are the Treatments Tested in This Trial?

Interventions

• Retroperitoneal Lymph Node Dissection

Trial Overview The study is testing the effectiveness of Retroperitoneal Lymph Node Dissection (RPLND) surgery in treating testicular seminoma that has potentially spread to abdominal lymph nodes. The goal is to see if this procedure can reduce long-term health issues like second cancers or heart disease.

How Is the Trial Designed?

Group I: Treatment (RPLND) Experimental Treatment 2 Interventions

Patients undergo RPLND.

Who Is Running the Clinical Trial?

University of Southern California

Lead Sponsor

Trials

956

Recruited

1,609,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Citations

1. sciencedirect.com sciencedirect.com/science/article/pii/S1078143924000140

Primary retroperitoneal lymph node dissection for clinical ... Primary RPLND is a safe and effective treatment option for patients with CS II seminomatous TGCT resulting highly promising cure rates combined with low ...

2. urotoday.com urotoday.com/conference-highlights/asco-gu-2025/asco-gu-2025-penile-urethral-testicular-and-adrenal-cancers/158444-asco-gu-2025-primary-retroperitoneal-lymph-node-dissection-in-stage-ii-seminoma-management-strategies-and-current-controversies.html

Primary Retroperitoneal Lymph Node Dissection in Stage II ... Overall excess non-testicular cancer mortality was 23% compared to the general population, with increased risks after platinum-based ...

3. clinicaltrials.gov clinicaltrials.gov/study/NCT02537548

NCT02537548 | Retroperitoneal Lymph Node Dissection in ... This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma.

4. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/36913642/

Surgery in Early Metastatic Seminoma: A Phase II Trial of ... RPLND is a treatment option for testicular seminoma with clinically low-volume retroperitoneal lymphadenopathy and is associated with low long-term morbidity.

5. clinicaltrials.gov clinicaltrials.gov/study/NCT06932458

NCT06932458 | A Clinical Trial of Primary Retroperitoneal ... A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases (RPLND-Seminoma).

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12070901/

Feasibility and Oncological Safety of Robotic ... We found that robotic RPLND results in a shorter operative time and hospital stay and has fewer severe complications, without increasing the risk of recurrence.

7. cinj.org cinj.org/lymph-node-removal-procedure-first-line-treatment-testicular-seminoma-associated-favorable-survival

Lymph Node Removal Procedure as First-Line Treatment ... A surgical procedure, when used as a first-line therapy for a form of testicular cancer known as seminoma, is associated with favorable survival rates.

8. sciencedirect.com sciencedirect.com/science/article/pii/S2666168324003781

Primary Retroperitoneal Lymph Node Dissection as ... RPLND as primary treatment is an option for selected low-stage seminomas with a limited burden of disease, showing low complications and low relapse rates.